Avalanche Biotechnologies Inc Logo Image

Avalanche Biotechnologies Inc

Most Recent Annual Report

2015 Form 10K

Avalanche Biotechnologies Inc

Avalanche Biotechnologies Inc does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



About Avalanche Biotechnologies Inc

Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on discovering and developing novel gene therapies for the treatment of ophthalmic diseases based on its Ocular BioFactory platform. Its lead product candidate includes AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, an anti-vascular endothelial growth factor protein product candidate for the prevention of wet AMD; and AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.

Ticker:
AAVL
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol